MEDICINES
PATIENT ASSISTANCE PROGRAMS
IMPORTED MEDICINES
CONTACT US
Upload
Introduction to Xovoltib 40mg Tablet
Xovoltib 40mg Tablet contains Afatinib dimaleate as its active component, serving as an anticancer medication. It is prescribed for individuals with non-small cell lung cancer (NSCLC) whose tumors exhibit specific (non-resistant) abnormal epidermal growth factor receptor (EGFR) genes. Additionally, it is recommended for patients with metastatic squamous NSCLC that progresses after undergoing platinum-based chemotherapy. Cancer is characterized by abnormal and uncontrolled cell multiplication. Prior to using this medication, it is crucial to discuss any kidney disorders, breathing issues, liver disorders, heart problems, intolerance to sugars, severe dry eye, or other eye-related concerns with your doctor.
Xovoltib 40mg Tablet has the potential to postpone the progression of the disease and enhance overall survival. Moreover, it contributes to sustaining a higher quality of life for an extended duration. This improvement encompasses enhanced physical functionality, diminished pain, and heightened mental and emotional well-being. Inform your doctor if you wear contact lenses or are breastfeeding prior to initiating this medication. Due to the medicine’s potential to increase skin sensitivity to the sun, it is advisable to limit sun exposure. This medication is not advisable for use in individuals under the age of 18, and discontinuation should only be done under the guidance of a doctor.
Uses of Xovoltib 40mg Tablet
- Non-small cell lung cancer (NSCLC)
Therapeutic Effects of Xovoltib 40mg Tablet
Xovoltib 40mg Tablet’s therapeutic impact is mainly linked to its capacity to hinder the activity of specific proteins within cancer cells, specifically those belonging to the epidermal growth factor receptor (EGFR) family. These proteins are pivotal in fostering the growth and dissemination of cancer cells, and by impeding their activity, the medication can aid in decelerating or halting the advancement of cancer.
Interaction of Xovoltib 40mg Tablet with other drugs
Xovoltib 40mg Tablet exerts its therapeutic effect by primarily targeting and inhibiting specific proteins in cancer cells, particularly those belonging to the epidermal growth factor receptor (EGFR) family. These proteins play a crucial role in facilitating the growth and dissemination of cancer cells. By blocking their activity, the medication contributes to slowing down or halting the progression of cancer.
More Information about Xovoltib 40mg Tablet
- Xovoltib 40mg Tablet should be stored at room temperature, between 40°C to 25°C (68°F to 77°F).
- Protected from light.
- Keep it in its original packaging until it is ready to be used.
- Keep out of the reach of children and pets.
- Should be disposed of properly.
How to consume Xovoltib 40mg Tablet
Xovoltib 40mg Tablet is an oral medication typically taken once daily, around the same time, with or without food. It is important to follow the prescribed dosage as instructed by a doctor. Swallow the capsules whole with a glass of water; avoid crushing, chewing, or opening them, as this may impact the medication’s absorption and reduce its efficacy. Do not take a double dose to compensate for a missed one.
Safety Advices for Xovoltib 40mg Tablet
Pregnancy
Xovoltib 40mg Tablet is not recommended during pregnancy as it can pose a risk of fetal harm. It is advised to avoid this medication if pregnant.
Breast Feeding
The excretion of Xovoltib 40mg Tablet in human milk is uncertain, and the potential risks to a nursing infant are not known. Therefore, breastfeeding women should seek advice from a healthcare provider before using this medication.
Lungs
Xovoltib 40mg Tablet is mainly prescribed for the treatment of non-small cell lung cancer (NSCLC). Patients with any other lung diseases should seek guidance from healthcare providers before initiating this medication.
Liver
Xovoltib 40mg Tablet undergoes primary metabolism in the liver. Therefore, it is important to notify your healthcare provider of any existing liver problems or diseases. The medication may elevate liver enzymes, indicating potential liver damage or inflammation. Patients on this medication should undergo regular blood tests to monitor their liver function.
Alcohol
It is advisable to refrain from alcohol consumption while using Xovoltib 40mg Tablet, as alcohol can heighten the risk of specific side effects linked to the medication, such as stomach ulcers or gastrointestinal bleeding.
Driving
Patients taking Xovoltib 40mg Tablet should be cautioned against driving or operating machinery if they encounter side effects such as fatigue, dizziness, or blurred vision, which may compromise their ability to do so safely.
Side Effects of Xovoltib 40mg Tablet
Similar to all medications, Xovoltib 40mg Tablet may induce side effects, although not everyone who uses it will necessarily encounter them.
Serious:
- Interstitial lung disease (ILD)
- Severe diarrhea or dehydration
- Liver problems
- Eye problems, such as corneal erosion or ulceration
- Hemorrhage or bleeding problems
- Kidney problems
- Cardiac problems
Common:
- Diarrhea
- Mouth sores
- Acne or skin rash
- Nausea and vomiting
- Fatigue
- Loss of appetite
- Abdominal pain
- Nail changes, such as nail bed infections or inflammation
- Dry skin or itching
- Eye irritation or dryness
- Respiratory infections
Word of Advice
Adhere to all instructions and dosage recommendations provided by your healthcare provider. Refrain from taking more or less of the medication than prescribed. Promptly inform your healthcare provider of any new or worsening symptoms, particularly those related to your lungs, eyes, skin, liver, kidneys, heart, or bleeding. Ensure adequate hydration and report any signs or symptoms of dehydration, especially in cases of severe diarrhea. Women should avoid pregnancy or breastfeeding, and reproductive-age women must use effective birth control during the treatment and for at least two weeks after their final dose. Report any indications of dehydration, such as dry mouth or reduced urination, to your healthcare provider without delay.
FAQs
Q 1. Can I donate blood while taking Xovoltib 40mg Tablet?
While using Xovoltib 40mg Tablet, patients should refrain from donating blood, as the medication can be detrimental to the recipient. It is crucial to notify your healthcare provider if you intend to donate blood, as they may recommend waiting until after you have completed the treatment.
Q 2. Can I continue to work or go to school while taking Xovoltib 40mg Tablet?
The feasibility of working or attending school while on Xovoltib 40mg Tablet will vary based on your individual condition and response to treatment. Certain patients may encounter fatigue or other side effects that could affect their capacity to carry out daily activities.
Q 3. Does Xovoltib 40mg Tablet have any effect on fertility?
Information regarding the impact of Xovoltib 40mg Tablet on fertility is limited. Nevertheless, it is crucial to notify your healthcare provider if you are attempting to conceive, as certain cancer treatments may influence fertility.
Q 4. Can I take Xovoltib 40mg Tablet if I have a history of heart problems?
If you have a history of heart problems, it is crucial to consult with your healthcare provider about the potential risks and benefits of initiating treatment with Xovoltib 40mg Tablet. This medication has the potential to cause cardiac issues, and your healthcare provider may need to closely monitor you throughout the course of treatment.
Q 5. Can Xovoltib 40mg Tablet be used in combination with other cancer treatments?
Xovoltib 40mg Tablet is occasionally employed in conjunction with other cancer treatments, such as chemotherapy or immunotherapy. The safety and efficacy of these combinations are contingent upon your specific condition and treatment regimen.
Fact Box of Xovoltib 40mg Tablet
Molecule name: Afatinib dimaleate
Pharmacological class: Tyrosine kinase inhibitor
Therapeutic class: Anticancer
Indications:
1. Non-small cell lung cancer (NSCLC)
References
- Boehringer Ingelheim Pharmaceuticals, Inc, US Food and Drug Administration, [ Revised on Jan 2018] [ Accessed on 21st April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf
- Boehringer Ingelheim International GmbH, Electronic medicines compendium (EMC), [ Revised on Sept 2020] [ Accessed on 21st April 2023], https://www.medicines.org.uk/emc/files/pil.5147.pdf
- Helga Wecker, Cornelius F Waller; Afatinib; Recent Results in Cancer Research 2018; https://pubmed.ncbi.nlm.nih.gov/30069769/
Reviews
There are no reviews yet.